Amicapsil’s effect on pressure injuries in SCI
Read more
Read more
Both studies find 100% closure rates
for acute and chronic pressure injuries
are on NHS Supply Chain
quicker than antibiotics and antiseptics.
Effective on resistant infections and does not contribute to AMR.
Effective on resistant infections and does not contribute to AMR.
Effective on resistant infections and does not contribute to AMR.
Review article discussing
the wound microbiome and Amicapsil
Review article discussing
the wound microbiome and Amicapsil
Review article discussing
the wound microbiome and Amicapsil
acting via the skin and wound microbiome without the use of antimicrobials.
acting via the skin and wound microbiome without the use of antimicrobials.
acting via the skin and wound microbiome without the use of antimicrobials.
Effective wound treatment in immunocompetent and immunocompromised persons.
Effective wound treatment in immunocompetent and immunocompromised persons.
Effective on antibiotic and antiseptic resistant wound infections.
Effective in immunocompetent and immunocompromised persons.
The Microbiome Supporting Soap is ideal for sensitive skin, including the skin of babies and toddlers.
The Microbiome Supporting Soap is ideal for sensitive skin, including the skin of babies and toddlers.
The Microbiome Supporting Soap is ideal for sensitive skin, including the skin of babies and toddlers.
“From 4 weeks of absolute hell – to being pain-free, getting a full night’s sleep and back to normal at work.”
“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”
“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”
NH ( patient)
NH ( patient)
NH ( patient)
Effective in treating severe infections, including infections not responding to antibiotics and antiseptics.
Effective in treating severe infections, including infections not responding to antibiotics and antiseptics.
Effective in treating severe infections, including infections not responding to antibiotics and antiseptics.
60% quicker removal of infection than antibiotics and antisepics.
60% quicker removal of infection than antibiotics and antisepics.
60% quicker removal of infection than antibiotics and antisepics.
No additives or chemicals
No additives or chemicals
No additives or chemicals
Infection causes pain and by removing the infection, Amicapsil and SertaSil reduce the pain.
Infection causes pain and by removing the infection, Amicapsil and SertaSil reduce the pain.
Infection causes pain and by removing the infection, Amicapsil and SertaSil reduce the pain.
Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.
Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.
Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.
climate change
VH (patient)
VH (patient)
VH (patient)
it is biologically recyclable and does not require the use of chemicals, plastics or antimicrobials.
Willingsford Ltd.
Willingsford is a British healthcare company. It was founded in 2010 for the purpose of pursuing MPPT in wound healing.
At the time, studies had demonstrated that the technology was effective in wound healing, but for commercialisation, the technology still had a long way to go. The mode-of-action was not completely understood, it was necessary to develop the manufacturing process and to achieve regulatory approval. Willingsford was therefore established and with the help of a UK government grant, the goal of gaining the CE-mark was achieved in July 2016.
Following approval, products based on MPPT were launched in the UK and the rest of Europe.
In March 2017, Willingsford received a second UK government grant to support the further development of MPPT.
Since launch, MPPT has been used by several hospitals and in community care and it has been able to promote the healing of a number of “non-healing” wounds. Many have described MPPT as a disruptive technology because it is based on completely new principles and because it can help wounds that no longer could be helped by existing approaches. However, its novelty also means that its acceptance takes time. It has been estimated that it takes around 9-10 years for a new technology to be fully accepted by the medical profession.
MPPT is available for human and veterinary wound healing in the EU and efforts to seek regulatory approval in other territories are ongoing.
In parallel with these activities, Willingsford is actively pursuing a number of other healthcare technologies.
Willingsford is looking for partners and distributors around its wound healing technology.